Primary renal tumour shrinkage in patients (pts) who did not undergo upfront cytoreductive nephrectomy (uCN): Subgroup analysis from the phase III JAVELIN Renal 101 trial of first-line avelumab plus axitinib (A plus Ax) vs sunitinib (S) for advanced renal cell carcinoma (aRCC)

被引：0
|
作者：
Albiges, L. [1 ]
Rini, B. I. [2 ]
Haanen, J. B. A. G. [3 ]
Motzer, R. J. [4 ]
Kollmannsberger, C. K. [5 ]
Negrier, S. [6 ]
Nole, F. [7 ]
Bedke, J. [8 ]
Bilen, M. A. [9 ]
Nathan, P. [10 ,11 ]
Tomita, Y. [12 ]
Huang, B. [13 ]
Ching, K. A. [14 ]
Chudnovsky, A. [15 ]
Robbins, P. B. [16 ]
di Pietro, A. [17 ]
Thomaidou, D. [18 ]
Choueiri, T. K. [19 ,20 ]
机构：
[1] Inst Gustave Roussy, Med Oncol, Villejuif, France
[2] Cleveland Clin, Oncol, Cleveland, OH 44106 USA
[3] Netherlands Canc Inst, Med Oncol, Amsterdam, Netherlands
[4] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA
[5] British Columbia Canc Agcy, Dept Med Oncol, Vancouver Ctr, Vancouver, BC, Canada
[6] Univ Lyon, Ctr Leon Berard, Med Oncol, Lyon, France
[7] Ist Europeo Oncol, Med Oncol Div Urogenital & Head & Neck Tumours, Milan, Italy
[8] Univ Tubingen, Urol, Tubingen, Germany
[9] Emory Univ, Winship Canc Inst, Hematol & Med Oncol, Atlanta, GA 30322 USA
[10] Mt Vernon Canc Ctr, Canc Serv, London, England
[11] East North Herts NHS Trust, London, England
[12] Niigata Univ, Dept Urol, Dept Mol Oncol, Grad Sch Med, Niigata, Japan
[13] Pfizer Inc, Biostat, Groton, CT 06340 USA
[14] Pfizer Inc, Biostat, San Diego, CA USA
[15] Pfizer Inc, Immunooncol, Cambridge, MA USA
[16] Pfizer Inc, Translat Oncol, San Diego, CA USA
[17] Pfizer Inc, Clin Dev, Milan, Italy
[18] Pfizer Hellas, Med Affairs, Athens, Greece
[19] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Dept Genitourinary Oncol, Boston, MA 02115 USA
[20] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
908PD
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial
    Bilen, Mehmet A.
    Rini, Brian, I
    Voss, Martin H.
    Larkin, James
    Haanen, John B. A. G.
    Albiges, Laurence
    Pagliaro, Lance C.
    Voog, Eric G.
    Lam, Elaine T.
    Kislov, Nikolay
    McGregor, Bradley A.
    Lalani, Aly-Khan A.
    Huang, Bo
    di Pietro, Alessandra
    Krulewicz, Stan
    Robbins, Paul B.
    Choueiri, Toni K.
    CLINICAL CANCER RESEARCH, 2022, 28 (04) : 738 - 747
  • [22] Efficacy of avelumab plus axitinib (A plus Ax) versus sunitinib (S) by IMDC risk group in advanced renal cell carcinoma (aRCC): Extended follow- up results from JAVELIN Renal 101.
    Haanen, John B. A. G.
    Larkin, James
    Choueiri, Toni K.
    Albiges, Laurence
    Rini, Brian I.
    Atkins, Michael B.
    Schmidinger, Manuela
    Penkov, Konstantin
    Thomaidou, Despina
    Wang, Jing
    Mariani, Mariangela
    Di Pietro, Alessandra
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [23] Impact of Prior Cytoreductive Nephrectomy on Efficacy in Patients with Synchronous Metastatic Renal Cell Carcinoma Treated with Avelumab plus Axitinib or Sunitinib: Post Hoc Analysis from the JAVELIN Renal 101 Phase 3 Trial
    Grimm, Marc-Oliver
    Oya, Mototsugu
    Choueiri, Toni K.
    Motzer, Robert J.
    Schmidinger, Manuela
    Quinn, David I.
    Gravis-Mescam, Gwenaelle
    Verzoni, Elena
    Van den Eertwegh, Alfonsus J. M.
    di Pietro, Alessandra
    Mariani, Mariangela
    Wang, Jing
    Thomaidou, Despina
    Albiges, Laurence
    EUROPEAN UROLOGY, 2024, 85 (01) : 8 - 12
  • [24] Efficacy of avelumab plus axitinib vs sunitinib by IMDC risk group in advanced renal cell carcinoma (aRCC): extended follow-up results from JAVELIN Renal 101
    Haanen, John
    Larkin, James
    Choueiri, Toni
    Albiges, Laurence
    Rini, Brian
    Atkins, Michael
    Schmidinger, Manuela
    Penkov, Konstantin
    Thomaidou, Despina
    Wang, Jing
    Mariani, Mariangela
    di Pietro, Alessandra
    Motzer, Robert
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 51 - 51
  • [25] Impact of Prior Cytoreductive Nephrectomy on Efficacy in Patients with Synchronous Metastatic Renal Cell Carcinoma Treated with Avelumab plus Axitinib or Sunitinib: Post Hoc Analysis from the JAVELIN Renal 101 Phase 3 Trial.
    Froehner, Michael
    EUROPEAN UROLOGY, 2024, 86 (05)
  • [26] Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial
    Larkin, James
    Oya, Mototsugu
    Martignoni, Marcella
    Thistlethwaite, Fiona
    Nathan, Paul
    Ornstein, Moshe C.
    Powles, Thomas
    Beckermann, Kathryn E.
    Balar, Arjun, V
    McDermott, David
    Gupta, Sumati
    Philips, George K.
    Gordon, Michael S.
    Uemura, Hirotsugu
    Tomita, Yoshihiko
    Wang, Jing
    Michelon, Elisabete
    di Pietro, Alessandra
    Choueiri, Toni K.
    ONCOLOGIST, 2022, : 333 - 340
  • [27] Phase 3 study of avelumab in combination with axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma (aRCC)
    Motzer, R. J.
    Choueiri, T.
    Larkin, J.
    Albiges, L.
    Haanen, J. B.
    Schmidinger, M.
    Atkins, M. B.
    Mariani, M.
    Shnaidman, M.
    Di Pietro, A.
    Rini, B. I.
    ANNALS OF ONCOLOGY, 2016, 27
  • [28] Efficacy of avelumab plus axitinib (A plus Ax) versus sunitinib (S) by number of IMDC risk factors and tumor sites at baseline in advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101.
    Tomita, Yoshihiko
    Motzer, Robert J.
    Choueiri, Toni K.
    Rini, Brian I.
    Miyake, Hideaki
    Oya, Mototsugu
    Albiges, Laurence
    Fujii, Yosuke
    Umeyama, Yoshiko
    Wang Jing
    Di Pietro, Alessandra
    Schmidinger, Manuela
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [29] Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma
    Haanen, J. B. A. G.
    Larkin, J.
    Choueiri, T. K.
    Albiges, L.
    Rini, B. I.
    Atkins, M. B.
    Schmidinger, M.
    Penkov, K.
    Michelon, E.
    Wang, J.
    Mariani, M.
    di Pietro, A.
    Motzer, R. J.
    ESMO OPEN, 2023, 8 (03)
  • [30] C-reactive protein (CRP) as a predictive marker for outcomes with avelumab plus axitinib (A plus Ax) in patients with poor-risk advanced renal cell carcinoma (aRCC): Exploratory analysis from JAVELIN Renal 101.
    Tomita, Yoshihiko
    Motzer, Robert J.
    Choueiri, Toni K.
    Rini, Brian I.
    Uemura, Hirotsugu
    Oya, Mototsugu
    Albiges, Laurence
    Fujii, Yosuke
    Umeyama, Yoshiko
    Huang, Bo
    Di Pietro, Alessandra
    Schmidinger, Manuela
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
12345